Targeting the lateral neck of superior articular process and sub-mammillary fossa for lumbar medial branch radiofrequency ablation: A case series.

Introduction: Lumbar medial branch (MB) radiofrequency ablation (RFA) is a common image-guided procedure to treat facetogenic low back pain. Recent anatomical literature has proposed a two-lesion RFA approach targeting the posterior portion of the lateral neck of superior articular process (SAP) and the superior aspect of the sub-mammillary fossa. The objectives of this report were to: 1) describe the novel lumbar MB RFA technique, 2) discuss the relevant anatomy, and 3) report pain relief outcomes in four patients who gave informed consent to be treated with the novel two-landmark lumbar MB RFA technique.

The effectiveness of sacral lateral branch radiofrequency neurotomy for posterior sacroiliac joint complex pain in patients selected by dual sacral lateral branch blocks; A real-world cohort study.

Background: Previous study of spinal neurotomy procedures indicates that stringent block selection improves outcomes. However, this pattern is not established for sacral lateral branch radiofrequency neurotomy (SLBRFN). Few SLBRFN studies have used stringent block selection criteria such as ≥80 % pain reduction following dual sacral lateral branch blocks (SLBB).

A description and outcome evaluation of sacrococcygeal joint radiofrequency neurotomy for treatment of chronic coccydynia - A dorsal approach.

Background: Coccydynia is a condition characterized by pain and tenderness in the coccyx region of the spine. Chronic coccydynia (≥3-months) management remains a clinical challenge. Radiofrequency neurotomy (RFN) targeting the sacrococcygeal joint (SCJ) and/or 1st intercoccygeal joint (ICJ) margins has emerged as an alternative, minimally invasive intervention for refractory coccydynia.

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.

Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based vaccine (Ad26.Mos4.HIV) at Months 0, 3, 6, 12 and alum-adjuvanted clade C gp140 at Months 6, 12.